<DOC>
	<DOC>NCT01374490</DOC>
	<brief_summary>This study is being conducted to evaluate the safety and tolerability of crofelemer 125 mg twice a day, taken orally, over 48 weeks of therapy in human immunodeficiency virus-positive (HIV+) subjects with diarrhea.</brief_summary>
	<brief_title>Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>HIV Enteropathy</mesh_term>
	<criteria>Male or female ≥ 18 years old History of HIV1 infection On an antiretroviral therapeutic regimen for treatment of HIV1 disease and associated conditions (including prophylactic antibiotics for Pneumocystis jirovecii or infection) for at least 4 weeks prior to screening Selfreported presence of diarrhea necessitating ADM use for at least 4 weeks CD4 counts &lt; 100 cells/mm3 Oral temperature greater than 38.0° C, or unintentional weight loss of 5.0 kg or greater during the prior 2 months Bright red blood per rectum judged not to be of an anal (e.g., hemorrhoid, fissure) origin Immediate need for GI surgery or intervention for active GI bleeding, pancreatitis, peritonitis, intestinal obstruction, or intraabdominal abscess</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV +</keyword>
	<keyword>HIV positive</keyword>
	<keyword>HIV associated diarrhea</keyword>
	<keyword>AIDS</keyword>
	<keyword>Diarrhea</keyword>
</DOC>